GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-21

Study Completion Date

2024-10-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale:

Efficacy study (RCT) for glycosaminoglycan(GAG)-therapy for the indication bladder pain syndrome / interstitial cystitis with Hunner lesion subtype (BPS-IC H+). reason for this study is a current lack of evidence regarding its efficacy and cost-effectiveness.

Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain and Quality of Life (QOL)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real-world Evidence Study on Cystistat

NCT05544695

Interstitial Cystitis and Bladder Pain Syndrome

COMPLETED

Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome

NCT00919113

Interstitial Cystitis Painful Bladder Syndrome

COMPLETED PHASE2

URACYST® For the Treatment of GAG Deficient Interstitial Cystitis

NCT00150488

Painful Bladder Syndrome Interstitial Cystitis

COMPLETED NA

Interstitial Cystitis

NCT00056251

Interstitial Cystitis

COMPLETED PHASE2

Biopsychosocial and Conventional Approach in Bladder Pain Syndrome

NCT05155384

Interstitial Cystitis Bladder Pain Syndrome

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

Reimbursement in the Netherlands for GAG-therapy for bladder pain syndrome / interstitial cystitis patients with Hunner lesion subtype (BPS-IC H+) is under debate, as evidence regarding its efficacy and cost-effectiveness is lacking.

Objective:

Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain. Secondary objectives are to determine the 1) cost-effectiveness of GAG therapy, 2) effectiveness of GAG therapy on quality of life and bladder inflammation evaluated by urethrocystoscopy

Study design:

Multi-design study. Study is powered and set-up as double-blinded randomized intervention study and is extended with a double-blinded aggregated N-of-1 trial. As requested by the Zorginstituut Netherlands, the study will be further extended with a prospective, non-blinded intervention study to evaluate long term follow up with a low frequency therapy dose.

Study population:

People with symptomatic BPS-IC H+ (\> 18 yrs old). A total of 80 patients will be included for the main study.

Intervention :

GAG bladder instillations (hyaluronic acid + chondroitin sulfate; Ialuril) 50ml administered with a catheter. Placebo will be Hypromellose 50ml administered with a catheter. Patients will receive instillations (Ialuril / placebo with ratio 2:1) in 3 periods of 6 wks with frequency of 1 instillation/wk. With wash-out periods 4 wks. After 3 periods of treatment / placebo (wk 30), blinding will cease and continue unblinded where all subjects will receive maintenance therapy Ialuril for 1x/4wk until 54 weeks (endpoint).

Main study parameters/endpoints:

Primary outcome parameter: change from baseline in maximum bladder pain (visual analogue scale (VAS) pain score (3d average and maximal pain score).

Secondary outcome parameters:

* Change from baseline in VAS score (0-10) on self-reported secondary symptoms
* Change from baseline from self-reported Global Assessment of Improvement (Likert scale)
* Change from baseline from O'Leary-Sant IC Symptom Index \& Problem Index questionnaire
* Change from baseline in urethrocystoscopic evaluation of bladder mucosa (inflammation, active Hunner lesions) (clinician assessed estimated % of inflammation \& degree of inflammation)
* Change from baseline in Quality of Life using ED-5D 5L questionnaire (Dutch)
* Cost effectiveness analyses using iMCQ and iPCQ questionnaires
* Changes in Patient Reported Outcome questionnaire (incl. urinary frequency)
* Adverse events using Clavien-Dindo system

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Benefits patients and group relatedness. All participants are capacitated adults and will receive a similar amount of intervention and placebo treatments. Treatment corresponds to the Dutch NVU guideline BPS. Therapy will be reimbursed for patients. During 54wks, patients will have a 6 week period where placebo is given. Due to the study design, patients can obtain a personal (individual) study efficacy result if therapy was successful in him/her.

Therapy and placebo: risks and burden This study will be submitted as low-intervention trial. GAG therapy (instillations) has been used for \>25 yrs in clinical practice to treat BPS-IC. GAG-therapies are registered as medical devices. The therapy is instilled into the bladder using a catheter (by nurse / patient). Catherization has a small increased risk for developing an urine tract infection (1.9%) \[Herr 2015\], urethral discomfort and in rare cases urethral trauma.

The placebo compound Hypromellose 0.3% is used as moisturizing drops to treat dry eyes. It is inert (non-irritating and hypo-allergenic). Very rare (\< 0.01%) side effects are reported in the Dutch 'Farmacologisch Kompas'. They report local side effects of sensitivity (burning, itch, tears e.d.). Blurry vision. and very rare systemic effects as rash, itch.Because of these reported side effects at inclusion the (over)sensitivity is checked by one drop in an eye, taking into account the possible blurry vision afterwards.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Pain Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Study start as a normal double blinded RCT, but continues with an aggregated N-of-1 (multi-crossover) type trial

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

double blinded by care provider (person giving the treatment) and the participant (blinded syringes en placebo product)

Intervention Type DEVICE

GAG therapy (bladder instillations with glycosaminoglycans)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IALURIL Prefill

GAG therapy (bladder instillations with glycosaminoglycans)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult patients (18 yrs or older) with symptomatic BPS with established Hunner lesions objectified with urethrocystoscopy in the 3 months prior to inclusion.
2. A VAS pain score (maximum pain during the last 3 days; scale 0-10) of at least 4.

Exclusion Criteria

1. pain, discomfort in pelvic region of inflammatory bladder conditions due to any cause other than BPS with Hunner lesions, with the exception of irritable bowel syndrome (IBS) and hypertonic pelvic floor or urine tract infections (UTI; \<3 UTI's / year). This is noted by ESSIC as a confusable disease \[van de Merwe 2007, contains an elaborate table for this\].
2. had a urine tract infection in the previous 6 weeks.
3. received bladder instillations for BPS in the previous 3 months;
4. received intradetrusor Botulinum toxin (BOTOX) injections within the previous 12 months.
5. received transurethral coagulation/ablation therapy of Hunner lesions within the last 12 months, with the exception of patients who have objectified Hunner lesion recurrence(s) on cystoscopy after coagulation/ablation therapy after at least 3 months' post-intervention.
6. started a new treatment for (chronic) pain (pharmacotherapy) or urine tract infection in the last month.
7. Unable (also legal) to give informed consent.
8. Allergic to Hypromellose (tested in one eye)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No